Inactive Instrument

Zenyth Therapeutics Limited Stock

ZTL

AU000000ZTL7

Zenyth Therapeutics, Ltd. develops pharmaceutical and biotechnology products in the therapeutic areas of hematology, bladder cancer and anti-virals. The Company's core business is the research and development medicines to treat human diseases. Zenyth's in-house pharmaceutical R&D is focused on three key areas: infectious diseases, neurological disease, and allergy and inflammation. Its R&D activity targets the clinical development of compounds for serious chronic human diseases.

Employees

Sector

Pharmaceuticals

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

Manager	Title	Age	Since
Andrew Nash CEO	Chief Executive Officer	-	-
Andrew Boyd DFI	Director of Finance/CFO	-	2011-02-28
S. D. B. Scrofani PRN	Corporate Officer/Principal	-	2011-02-28

Director	Title	Age	Since
Andrew Nash BRD	Director/Board Member	-	2011-02-28
Brian McNamee BRD	Director/Board Member	70	-
Antoni M. Cipa BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	-1.86%	+1.78%	+19.51%	-8.76%	66.56B
UCB	-2.04%	-3.49%	+49.68%	+221.00%	56.51B
SAMSUNG BIOLOGICS CO.,LTD.	+1.07%	+42.10%	+42.10%	+42.10%	42.98B
CSL LIMITED	+1.99%	+7.66%	-49.90%	-54.41%	40.46B
BIOGEN INC.	-1.46%	-2.24%	+62.74%	-25.69%	31.91B
MODERNA, INC.	+2.07%	+15.67%	+169.65%	-31.84%	31.65B
INCYTE CORPORATION	-1.58%	+0.31%	+70.98%	+82.98%	23.35B
INNOVENT BIOLOGICS, INC.	+3.08%	+13.05%	+9.63%	+195.27%	19.46B
SWEDISH ORPHAN BIOVITRUM AB	-0.13%	+3.03%	+66.64%	+132.04%	17.18B
Average	+0.10%	+8.76%	+49.00%	+61.41%	36.67B
Weighted average by Cap.	-0.23%	+7.31%	+43.19%	+53.60%

Zenyth Therapeutics Limited Stock

Stocks

ZTL

AU000000ZTL7

Pharmaceuticals

Managers and Directors: Zenyth Therapeutics Limited

Biopharmaceuticals

Company Profile

End-of-day quote Australian S.E. Other stock markets
-	-